Akero治疗学报告,肝硬化药物(efruxifermin)的2b阶段试验结果呈阳性。 Akero Therapeutics reports positive Phase 2b trial results for liver cirrhosis drug, efruxifermin.

Akero治疗学报告称,对因被称为MASH的疾病而患有肝硬化症的病人进行其药物efruxifermin(efruxifermin)第2b阶段试验,取得了积极成果。 Akero Therapeutics has reported positive results from a Phase 2b trial of its drug, efruxifermin, for patients with liver cirrhosis caused by a condition known as MASH. 试验显示,在96周的时间里,肝纤维化和安全情况有了显著改善。 The trial showed significant improvements in liver fibrosis and safety over 96 weeks. 该药物还改善了胰岛素敏感性和脂质新陈代谢的标记。 The drug also improved markers of insulin sensitivity and lipid metabolism. Akero目前正在进行第三阶段的试验。 Akero is now moving forward with Phase 3 trials.